Yew Bio Pharm Group Stock Total Asset
| YEWBDelisted Stock | USD 0.0002 0.00 0.00% |
Yew Bio Pharm Group fundamentals help investors to digest information that contributes to Yew Bio-Pharm's financial success or failures. It also enables traders to predict the movement of Yew Pink Sheet. The fundamental analysis module provides a way to measure Yew Bio-Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Yew Bio-Pharm pink sheet.
Yew |
Yew Bio Pharm Group Company Total Asset Analysis
Yew Bio-Pharm's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Yew Bio-Pharm Total Asset | 10.51 M |
Most of Yew Bio-Pharm's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Yew Bio Pharm Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Yew Bio Pharm Group has a Total Asset of 10.51 M. This is 99.96% lower than that of the Food Products sector and 99.9% lower than that of the Consumer Staples industry. The total asset for all United States stocks is 99.96% higher than that of the company.
Yew Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Yew Bio-Pharm's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Yew Bio-Pharm could also be used in its relative valuation, which is a method of valuing Yew Bio-Pharm by comparing valuation metrics of similar companies.Yew Bio is currently under evaluation in total asset category among related companies.
Yew Fundamentals
| Return On Equity | 0.0085 | |||
| Return On Asset | 0.011 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 9.23 M | |||
| Shares Outstanding | 59.19 M | |||
| Shares Owned By Insiders | 43.99 % | |||
| Price To Book | 0.0001 X | |||
| Price To Sales | 0.0002 X | |||
| Revenue | 27.31 M | |||
| Gross Profit | 3.53 M | |||
| EBITDA | 1.97 M | |||
| Net Income | 1.46 M | |||
| Cash And Equivalents | 28.45 K | |||
| Total Debt | 9.32 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 0.91 X | |||
| Cash Flow From Operations | 17.34 M | |||
| Earnings Per Share | 0.01 X | |||
| Number Of Employees | 35 | |||
| Beta | -0.81 | |||
| Market Capitalization | 17.76 K | |||
| Total Asset | 10.51 M | |||
| Retained Earnings | 25.07 M | |||
| Working Capital | 12.23 M | |||
| Current Asset | 16.87 M | |||
| Current Liabilities | 4.64 M | |||
| Z Score | 6.0 | |||
| Net Asset | 10.51 M |
About Yew Bio-Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Yew Bio Pharm Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Yew Bio-Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Yew Bio Pharm Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Yew Bio-Pharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Yew Bio-Pharm's short interest history, or implied volatility extrapolated from Yew Bio-Pharm options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Yew Pink Sheet
If you are still planning to invest in Yew Bio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Yew Bio-Pharm's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |